MedTrace Logo

Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP

NCT00374998 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2007-03-01

No results posted yet for this study

Summary

This study examines two new malaria vaccines (FP9-PP and MVA-PP) in healthy human volunteers to determine their safety and ability to induce a measurable immune response against malaria.

Conditions

Interventions

BIOLOGICAL

FP9-PP (FP9 polyprotein)

BIOLOGICAL

MVA-PP (Modified Virus Ankara polyprotein)

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • Wellcome Trust

    collaborator OTHER

  • European Vaccine Initiative

    lead OTHER

Principal Investigators

  • Adrian VS Hill, MA, BM BCh, DPhil, DM · University of Oxford

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-04-30
Completion
2007-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00374998 on ClinicalTrials.gov